Alongside their use for the treatment of DVT / PE and prevention of recurrent DVT / PE, anticoagulants can also be used to reduce the risk of secondary complications such as post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH).1,2
The phases of anticoagulation treatment may be categorised as initial, long-term (or continued) and extended.3
Adapted from Kearon et al. Thromb Haemost 2012.4
* Heparin, low molecular weight heparin (LMWH), fondaparinux. Initial therapy may be with oral apixaban for 7 days or rivaroxaban for 21 days.
† Includes LMWH and non-vitamin K antagonist oral anticoagulants (NOACs).
“In the absence of contraindications, [NOACs] should be preferred as first-line anticoagulant therapy in non-cancer patients with proximal DVT.”3
– ESC Consensus Statement, 2018
“When oral anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, dabigatran, edoxaban or rivaroxaban), a NOAC is the recommended form of anticoagulant treatment.”10
– ESC Guidelines, 2019
“In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy.”11
– ACCP Guidelines, 2016
More information on anticoagulants for the treatment and secondary prevention of VTE is provided later in the long-term prevention page.